Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2.
Krassimira Nanova, Abraham Zlotogorski, Yuval Ramot
Author Information
- Krassimira Nanova: Clalit Health Services, Jerusalem, Israel.
- Abraham Zlotogorski: Department of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Yuval Ramot: Department of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. ORCID
No abstract text available.
- J Virol. 2007 Dec;81(23):12758-65
[PMID: 17898056]
- Cutis. 2016 Jan;97(1):65-9
[PMID: 26919358]
- CMAJ. 2019 Sep 16;191(37):E1025-E1027
[PMID: 31527188]
- Clin Infect Dis. 2011 Apr 1;52(7):907-9
[PMID: 21273297]
- Pediatrics. 2002 Jun;109(6):1068-73
[PMID: 12042544]
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Chickenpox
Humans
SARS-CoV-2
Vaccination
COVID-19 Vaccines
BNT162 Vaccine
